Oxford Investment Consultants backs founders turning scientific research into products addressing global challenges.
Portfolio
6
companies
Caristo Diagnostics
Caristo Diagnostics develops AI-assisted tools for cardiac and vascular disease diagnostics.
Brill Power
Brill Power develops intelligent battery management systems to improve energy storage and vehicle performance.
Oxford Quantum Circuits
Oxford Quantum Circuits builds enterprise-ready quantum computing platforms.
Salience Labs
Salience Labs builds ultra high-speed multi-chip processors that combine photonics and electronics for artificial intelligence applications.
Navenio
Navenio provides indoor location technology and task allocation software to improve healthcare workflow efficiency.
Oxford Endovascular
Oxford Endovascular develops origami engineered medical devices to prevent brain haemorrhage.
The financing round was led by Oxford Science Enterprises and will support market expansion in the UK, EU, and United States.
"We are thrilled that five successful institutional investors participated in the financing round which validates the vast clinical and business potential of Caristo’s innovations"
The funding will support team growth and product development for energy storage and electric vehicles.
"As we grow our climate and clean energy platform, investing in Brill Power is an exciting move into energy storage technologies that are crucial to enable an increase of renewables on the power grid, electrification of transport, and to power our homes, businesses and key infrastructure. Through extended lifetimes, improved safety, and waste reduction, Brill Power’s work is setting a new standard for how to store and use clean power to accelerate progress to our net zero emissions goals."
The financing was co-led by Lansdowne Partners and The University of Tokyo Edge Capital Partners.
"Quantum computing promises to be the next frontier of innovation, and OQC, with its state-of-the-art Coaxmon technology, aims to integrate the forefront of modern physics into our everyday lives. UTEC is honoured to be part of OQC’s mission of making quantum technology accessible to all and will support OQC’s expansion into Asia-Pacific through collaborations with academia including the University of Tokyo, and partnerships with Japan’s leading financial and tech corporations."
The seed round was co-led by Cambridge Innovation Capital and Oxford Science Enterprises to accelerate the development of photonic artificial intelligence processors.
"Salience Labs brings together deep domain expertise in photonics, electronics and CMOS manufacture."
The Oxford Science Enterprises-led round will support US expansion and continued domestic growth in healthcare.
"I’m delighted our investors have again demonstrated their belief in the vast potential that Navenio can bring by ensuring ‘right person, right place, right time’. Artificial intelligence is one of many technologies making a real-world impact in the health sector, and this investment enables the company to rapidly spearhead international digital transformation."
The financing round was led by Vulpes Investment Management with backing from existing investors to fund first in-human data acquisition.
"The current device market for brain aneurysms is valued at well over $1bn and is growing rapidly year-on-year. One of the biggest challenges when it comes to treating neurovascular disease is having devices with high efficacy whilst minimising adverse events. Studies show that often multiple attempts are made to place treatment devices, as they often have challenges of landing accurately, opening and maintaining position. This can lead to adverse events and multiple devices being used. Procedures typically cost over $50,000 to treat a brain aneurysm and a next generation flow diverter overcoming unmet needs, offers the chance for more effective, safer and cost effective treatments as well as allowing many more patients to benefit. We plan to use this funding to bring Oxford Endovascular’s ground-breaking technology to the next stage and gain clinical data from human studies."
